The U.S. Food and Drug Administration’s draft Diversity Action Plan expectations have made diverse trial enrollment a strategic priority for sponsors—yet the institutional, relational, and community-level work that makes diverse enrollment possible happens at sites, with patients, and across organizations that no single voice can fully describe. This four-person panel session brings together a director from a safety-net hospital, a cancer survivor and patient advocate, a pharmaceutical sponsor representative, and an academic clinical research site physician leader to discuss their perspectives about diverse enrollment.
The session is a structured performance where each of the three learning objectives is anchored by a panelist and other views are raised in counterpoint. Attendees will leave with insights into structural barriers, trust-building practices, and an inter-institutional referral pathway framework they can adapt to their own workplace contexts.
CEU: 1.0 ACRP
Speakers:
Jeanette Carter, Cancer Survivor / Patient Advocate
Colleen Dodson-Honore, Healthcare Executive Director, Genentech - A Member of the Roche Group
Vijayakrishna Gadi, MD, PhD, Professor & Director of Medical Oncology / Deputy Director, UIC Cancer Center, University of Illinois Chicago
Claude Hall, Jr., MA, MHA, Director, Office of Government Grants Administration / Chair, Mount Sinai Hospital IRB, Sinai Health System